[{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Faes Farma S.A."},{"orgOrder":0,"company":"Norgine","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Norgine \/ Norgine B.V","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine B.V"},{"orgOrder":0,"company":"Norgine","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Covis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Norgine \/ Norgine B.V.","highestDevelopmentStatusID":"8","companyTruncated":"Norgine \/ Norgine B.V."},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Norgine","sponsor":"Fennec Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Norgine","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Norgine","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Norgine"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dantrolene","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Not Applicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Norgine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

                          Brand Name : Iwilfin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 15, 2024

                          Lead Product(s) : Eflornithine Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.

                          Brand Name : NPJ5008

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 26, 2024

                          Lead Product(s) : Dantrolene

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia, and New Zealand, the first approved therapy in the EU and UK to prevent cisplatin-induced ototoxicity.

                          Brand Name : Pedmarqsi

                          Molecule Type : Small molecule

                          Upfront Cash : $43.4 million

                          March 18, 2024

                          Lead Product(s) : Sodium Thiosulfate

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Recipient : Fennec Pharmaceuticals

                          Deal Size : $271.6 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.

                          Brand Name : Movicol

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 15, 2022

                          Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Goldman Sachs Asset Management

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).

                          Brand Name : PER977

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 04, 2021

                          Lead Product(s) : Ciraparantag

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Recipient : Covis Pharma

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality thera...

                          Brand Name : DFMO

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 23, 2021

                          Lead Product(s) : Eflornithine Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : US WorldMeds

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontro...

                          Brand Name : PER977

                          Molecule Type : Small molecule

                          Upfront Cash : $30.0 million

                          July 23, 2020

                          Lead Product(s) : Ciraparantag

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Recipient : AMAG Pharmaceuticals

                          Deal Size : $290.0 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 12, 2020

                          Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Faes Farma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank